Novartis markets Jakavi in ex-U.S. markets, leading to Incyte earning royalties and benefiting from FDA approval of Opzelura.

The entities involved

• Novartis →

  Swiss-American multinational pharmaceutical corporation

  • Novartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Sat 01:46
  • GSK and Novartis are identified as major pharmaceutical companies.Fri 02:16
• Incyte →

  American pharmaceutical company

  • Incyte, a biotech company based in Wilmington, outperformed the biotech ETF.Thu 13:11
• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Related events

• Novartis' trial results are impacting Royalty Pharma's investment decisions.Sep 5
• Novartis acquired Regulus Therapeutics in April, while also reportedly weighing a potential deal with Avidity Biosciences.Jun 7
• Novartis is shifting its R&D focus to India, moving operations outside of Switzerland.Sep 7
• Novartis operated through a wholly owned subsidiary in India on July 1, 2026.Jul 30
• Novartis sought Swissmedic regulatory approval for a drug, which was co-funded by Sida and introduced first in Ghana.Sep 15